3 stories mentioning HKG:2257Updated 16d ago
Every FINWIRES story that references HKG:2257, newest first.
Sirnaomics (HKG:2257) dosed the first patient in a phase II clinical trial of STP705 for aesthetic applications, according to a Thursday Hong Kong bourse filing.The product has been developed to deliver a minimally-invasive therapeutic alternative to conventional fat-reduction interventions.
Sirnaomics' (HKG:2257) Chairman Poon Hung Fai acquired 20,300 additional ordinary shares in the company, according to a Wednesday Hong Kong bourse filing.Shares of the biotechnology company were down nearly 4% in Thursday afternoon trading.The shares were purchased from the open market at an average price of HK$5 apiece on Wednesday.Poon now holds nearly 17.7 million, or 16.12%, shares in the company.
Sirnaomics (HKG:2257) said it agreed to issue HK$11.4 million worth of shares to an individual investor, according to a Monday filing with the Hong Kong bourse.The biotechnology company's shares gained nearly 12% in morning trade Tuesday.The company will issue 2.4 million shares at HK$4.69 apiece to Tse Shek Ho, a vice president of the group's corporate management department.Proceeds from the share sale will be used for general working capital.
